Cannabis and Opioid Use Disorder

University of Kentucky

Status and phase: Enrolling; Phase 1

Conditions: Opioid Use Disorder

Treatments: Drug: Inhaled vaporized cannabis; Drug: Intransal opioid

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05729932

75562-20242

1R01DA054347 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Current opioid use disorder

Exclusion criteria

• Current medical conditions that require medical management

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

15 participants in 2 patient groups

Intranasal Opioid Agonist

Experimental group

Description:

Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting).

Treatment:

Drug: Intransal opioid

Drug: Inhaled vaporized cannabis

Vaporized cannabis

Experimental group

Description:

Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer.

Treatment:

Drug: Intransal opioid

Drug: Inhaled vaporized cannabis